Your browser doesn't support javascript.
loading
Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case.
Klempner, Samuel J; Hendifar, Andrew; Waters, Kevin M; Nissen, Nicholas; Vail, Eric; Tuli, Richard; Mita, Alain.
Affiliation
  • Klempner SJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA.
  • Hendifar A; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Waters KM; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Nissen N; Department of Surgery, Division of Hepatobiliary Surgery, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Vail E; Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
  • Tuli R; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Mita A; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
JCO Precis Oncol ; 4: 614-619, 2020 Nov.
Article in En | MEDLINE | ID: mdl-35050748
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: JCO Precis Oncol Year: 2020 Document type: Article Affiliation country: Marruecos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: JCO Precis Oncol Year: 2020 Document type: Article Affiliation country: Marruecos Country of publication: Estados Unidos